Insulin glargine in the management of diabetes mellitus: An evidence-based assessment of its clinical efficacy and economic value

Core Evidence

Volumn 2, Issue 2, 2007, Pages 89-110

  Clissold, Rhian ^a   Clissold, Steve ^b  

^a FRENCHAY HOSPITAL   (United Kingdom)

^b Content Ed Net Communications SL ^*  (Spain)

Author keywords

Evidence based review; Glycemic control; Insulin glargine; Insulin therapy; Type 1 diabetes; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLIMEPIRIDE; HUMALOGMIX 25; HUMALOGMIX 50; HUMAN INSULIN; INSULIN ANTIBODY; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; METFORMIN; NOVOLIN R; PIOGLITAZONE; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADD ON THERAPY; ADULT DISEASE; BEDTIME DOSAGE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CHILDHOOD DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; EVIDENCE BASED PRACTICE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; LIPODYSTROPHY; MORNING DOSAGE; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PRURITUS; QUALITY OF LIFE; RANDOMIZATION; REVIEW; SIDE EFFECT;

EID: 38049070235     PISSN: 15551741     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. AACE (American Association of Clinical Endocrinologists). State of diabetes complications in America. Available at: http://www.stateofdiabetes.com (accessed January 2007).
2. ADA (American Diabetes Association). 2007 resource guide - a supplement to diabetes forecast. Available at: http://diabetes.org/diabetes-forecast/ resource-guide.jsp (accessed January 2007).
3. Alemzadeh R, Berhe T, Wyatt DT. Flexible insulin therapy with glargine insulin improved glycemic control and reduced severe hypoglycemia among preschool-aged children with type 1 diabetes mellitus. Pediatrics. 2005;115:1320-1324.
4. Ashwell SG, Gebbie J, Home PD. Optimal timing of injection of once-daily insulin glargine in people with type 1 diabetes using insulin lispro at meal-times. Diab Med. 2006a;23:46-52.
5. Ashwell SG, Gebbie J, Home PD. Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart. Diabet Med. 2006b;23:879-886.
6. Bode BW, Steed RD, Schleusener DS, Strange P. Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system. Endocr Pract. 2005;11:157-164.
7. Bolli G, Songini M, Trovati M; HOE901/4019 Italian study group. Transfer of patients with type 1 diabetes from NPH insulin to insulin glargine as basal insulin: a multicentre, randomized, parallel-group, open-label study. Diabetologia. 2006;49(Suppl. 1):607. Abstract 0993.
8. Bretzel RG, Nuber U, El-Haschimi K, Linn T; APOLLO study group. Equivalence of basal insulin glargine versus prandial insulin lispro for glucose control in type 2 diabetes patients on oral agents - results of the APOLLO study. Diabetologia. 2006;49(Suppl. 1):755. Abstract 0145.
9. Bullano MF, Fisher MD, Grochulski WD, Menditto L, Willey VJ. Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products. Am J Health Syst Pharm. 2006;63:2473-2482.
10. Chakkarwar PN, Manjrekar NA. Insulin glargine: a long acting insulin analog. J Postgrad Med. 2005;51:68-71.
11. Chan JL, Abrahamson MJ. Pharmacological management of type 2 diabetes mellitus: rationale for rational use of insulin. Mayo Clin Proc. 2003;78:459-467.
12. Chase HP, Arslanian S, White N, Usiskin K, Tamborlane W. Insulin glargine (GLAR) vs intermediate-acting insulin in adolescents with type 1 diabetes (T1DM) using multiple daily injection (MDI) therapy. Diabetologia. 2006;49(Suppl. 1):559-560. Abstract 0919.
13. Chatterjee S, Jarvis-Kay J, Rengarajan T, Lawrence IG, McNally PG, Davies MJ. Glargine versus NPH insulin: efficacy in comparison with insulin aspart in a basal bolus regimen in type 1 diabetes - the glargine and aspart study (GLASS). A randomized cross-over study. Diabetes Res Clin Pract. 2007;77:215-222.
14. Colino E, López-Capapé M, Golmayo L, Álvarez MA, Alonso M, Barrio R. Therapy with insulin glargine (Lantus®) in toddlers, children and adolescents with type 1 diabetes. Diabetes Res Clin Pract. 2005;70:1-7.
15. Currie CJ, Poole CD, Tetlow T, Holmes P, McEwan P. The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin. 2007;23(Suppl. 1):S33-S39.
16. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R; ATLANTUS study group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28:1282-1288.
17. DCCT (Diabetes Control and Complications Trial) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
18. DCCT (Diabetes Control and Complications Trial) Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. J Pediatr. 1994;125:177-188.
19. Dixon AN, Bain SC. Nausea and vomiting due to insulin glargine in patient with type 1 diabetes mellitus. BMJ. 2005;330:455.
20. Dixon B, Chase HP, Burdick J, et al. Use of insulin glargine in children under age 6 with type 1 diabetes. Pediatr Diabetes. 2005;6:150-154.
21. Dixon S, Peters JR. Evaluating the 'real' cost-effectiveness of health technology: reconciling the public interest with patients' interests. Curr Med Res Opin. 2007;23(Suppl. 1):S1-S6.
22. Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care. 2004;27:1554-1558.
23. Eliaschewitz FG, Calvo C, Valbuena H, et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res. 2006;37:495-501.
24. Fischer JS, McLaughlin T, Loza L, Beauchamp R, Schwartz S, Kipnes M. The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study. Curr Med Res Opin. 2004;20:1703-1710.
25. Fonseca V, Bell DS, Berger S, Thomson S, Mecca TE. A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a mulitcenter, randomized, parallel group study. Am J Med Sci. 2004;328:274-280.
26. Fritsche A, Schweitzer MA, Häring H-U; 4001 study group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized controlled trial. Ann Intern Med. 2003;138:952-959.
27. Fulcher GR, Gilbert RE, Yue DK. Glargine is superior to neutral protamine hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern Med J. 2005;35:536-542.
28. Garcia-Garcia E, Galera R, Aguilera P, Cara G, Bonillo A. Long-term use of continuous subcutaneous insulin infusion compared with multiple daily injections of glargine in pediatric patients. J Pediatr Endocrinol Metab. 2007;20:37-40.
29. Garg SK, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract. 2005;11:11-17.
30. Gerstein HC, Yale J-F, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with insulin Glargine for Hypoglycemia Treatment) study. Diabet Med. 2006;23:736-742.
31. Gomis R, Storms F, Conget I, Sinnassamy P, Davies M; AT.LANTUS study group. Improving metabolic control in sub-optimally controlled subjects with type 1 diabetes: comparison of two-treatment algorithms using insulin glargine. Diabetes Res Clin Pract. 2007;77:84-91.
32. Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Phamacoeconomics. 2007;25:253-266.
33. Grimaldi A, Vialettes B, Blayo A, Brun JM, Halimi S. Comparison of dinner with bedtime administration of insulin glargine in type 1 diabetic patients treated with basal-bolus regimen. Diabetes Metab. 2007;33:121-128.
34. Gummerson I. An update on insulin analogues. Pharm J. 2006;277:169-172.
35. Hamann A, Matthaei S, Rosak C, Silvestre L; HOE 901/4007 study group. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care. 2003;26:1738-1744.
36. Hathout EH, Fujishige L, Geach J, Ischandar M, Maruo S, Mace JW. Effect of therapy with insulin glargine (lantus) on glycemic control in toddlers, children, and adolescents with diabetes. Diabetes Technol Ther. 2003;5:801-806.
37. Heine RJ, Van Gaai LF, Johns D; GWAA study group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005;143:559-569.
38. Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000;23:644-649.
39. Herman WH, Ilag LL, Johnson SL, et al. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes. Diabetes Care. 2005;28:1568-1573.
40. Hershon KS, Blevins TC, Mayo CA, Rosskamp R. Once-daily insulin glargine compared with twice-daily NPH insulin in patients with type 1 diabetes. Endocr Pract. 2004;10:10-17.
41. Hirsch IB, Bode BW, Garg S, et al; Insulin Aspart CSII/MDI Comparison study group. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care. 2005;28:533-538.
42. HOE 901/2004 Study Investigators Group. Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in type 2 diabetic patients. Diabet Med. 2003;20:545-551.
43. Home PD, Rosscamp R, Forjanic-Klapproth J, Dressier A; European Insulin Glargine study group. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes, Diabetes Metab Res Rev. 2005;21:545-553.
44. IDF (International Diabetes Federation). Diabetes facts and figures. 2007a. Available at: http://www.idf.org/home/index.cfm?node=6 (accessed March 2007).
45. IDF (International Diabetes Federation). Global guideline for type 2 diabetes. 2007b. Available at: http://www.idf.org/home/index.cfm?unode=B7462CCB- 3A4C-472C-80E4-710074D74AD3 (accessed March 2007).
46. Jacober SJ, Scism-Bacon JL, Zagar AJ. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naive patients with type 2 diabetes receiving oral antidiabetes agents. Diabetes Obes Metab. 2006;8:448-455.
47. Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care. 2005;28:254-259.
48. Janka HU, Plewe G, Busch K. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. J Am Geriatr Soc. 2007;55:182-188.
49. Kacerovsky-Bielesz G, Dressler A, Freunscht R. Long-term glycemic control with insulin glargine in type 2 diabetes. Diabetes Res Clin Pract. 2006;71:184-191.
50. Kann PH, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes. 2006;114:527-532.
51. Karges B, Muche R, Riegger I, Moritz M, Heinze E, Debatin KM, et al. Injection of acidic or neutral insulin and pain: a single-center, prospective, controlled, noninterventional study in pediatric patients with type 1 diabetes mellitus. Clin Ther. 2006;28:2094-2101.
52. 1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care. 2006;29:1-8.
53. Lechleitner M, Roden M, Haehling E, Mueller M. Insulin glargine in combination with oral antidiabetic drugs as a cost-equivalent alternative to conventional insulin therapy in type 2 diabetes mellitus. Wien Klin Wochenschr. 2005;117:593-598.
54. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142-2148.
55. Luzio SD, Beck P, Owens DR. Comparison of the subcutaneous absorption of insulin glargine (Lantus®) and NPH insulin in patients with type 2 diabetes. Horm Metab Res. 2003;35:434-438.
56. Malone JK, Kerr LF, Campaigne BN, Sachson RA, Holcombe JH; Lisprc Mixture-Glargine study group. Combined therapy with insulin lispro mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther. 2004;26:2034-2044.
57. Malone JK, Bai S, Campaigne BN, Reviriego J, Augendre-Ferrante B. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycemic control in patients with type 2 diabetes. Diabet Med. 2005;22:374-381.
58. Manini R, Forlani G, Moscatiello S, Zannoni C, Marzocchi R, Marchesini G. Insulin glargine improves glycemic control and health-related quality of life in type 1 diabetes. Nutr Metab Cardiovasc Dis. 2007. In press. DOI:10.1016/j.numecd.2006.07.001.
59. Massi Benedetti MM, Humburg E, Dressler A, Ziemen M. A one-year, randomized, multicentre trial comparing insulin giargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res. 2003;35:189-196.
60. McEwan P, Poole CD, Tetlow T, Holmes P, Currie CJ. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. Curr Med Res Opin. 2007a;23(Suppl. 1):S7-S19.
61. McEwan P, Poole CD, Tetlow T, Holmes P, Currie CJ. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. Curr Med Res Opin. 2007b;23(Suppl. 1):S21-S31.
62. McKeage K, Goa KL. Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. Drugs. 2001;61:1599-1624.
63. Meneghini L, Schwartz S, Strange P, Oster G. Health-related quality of life and costs of receiving add-on therapy with insulin glargine or pioglitazone in patients with type 2 diabetes. Diabetologia. 2006;49(Suppl. 1):543. Abstract 0894.
64. Milicevic Z, Raz I, Strojek K, et al; HEART2D Study. Hyperglycemia and its effect after acute myocardial infarction on cardiovascular outcomes in patients with type 2 diabetes mellitus (HEART2D) study design. J Diabetes Complications. 2005;19:80-87.
65. Mortensen HB, Hougaard P. Comparison of metabolic control in a cross-sectional study of 2,873 children and adolescents with IDDM from 18 countries. Hvidøre Study Group on Childhood Diabetes. Diabetes Care. 1997;20:714-720.
66. Nathan DM, Cleary PA, Backlund JY, et al; Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
67. NICE (National Institute for Health and Clinical Excellence). Technology Appraisal Guidance 53. Guidance on the use of long-acting analogs for the treatment of diabetes - insulin glargine. London: NICE; December 2002. Available at: http://guidance.nice.org.uk/TA53/guidance/pdf/English/download.dspx (accessed January 2007).
68. 125I-labeled insulin glargine (HOE 901) in healthy men. Comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care. 2000;23:813-819.
69. Pan C-Y, Sinnassamy P, Chung K-D, Kim K-W; LEAD Study Investigators Group. Insulin glargine versus NPH insulin therapy in Asian type 2 diabetes patients. Diabetes Res Clin Pract. 2007;76:111-118.
70. Physicians' Desk Reference. Montvaie, NJ: Thomson Healthcare; 2007. Available at: http://www.pdr.net (accessed June 2007).
71. Pieber TR, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes. Diabetes Care. 2000;23:157-162.
72. Pieber TR, Treichel H-C, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabet Med. 2007;24:635-642.
73. Pinhas-Hamiel O, Zeitler P. The global spread of type 2 diabetes mellitus in children and adolescents. J Pediatr. 2005;146:693-700.
74. Poole CD, Tetlow T, McEwan P, Holmes P, Currie CJ. The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Curr Med Res Opin. 2007;23(Suppl. 1):S41-S48.
75. Porcellati F, Rossetti P, Pampanelli S, et al. Better long-term glycemic control with the basal insulin glargine as compared with NPH in patients with type 1 diabetes mellitus given meal-time lispro insulin. Diabet Med. 2004;21:1213-1220.
76. Powers AC. Diabetes mellitus. In: Kasper DL, Fauci AS, Longa DL, Braunwald E, Hauser SL, Jameson JL, eds. Harrison's principles of internal medicine. 16th ed. New York: McGraw-Hill; 2005, pp. 2152-2180.
77. Profit L. Exubra® (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetes. Core Evidence. 2005;1:90-101.
78. Raskin P, Klaff L, Bergenstal R, Hallé J-P, Donley D, Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care. 2000;23:1666-1671.
79. Raskin P, Allen E, Hollander P, et al; INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-265.
80. Raskin PR, Hollander PA, Lewin A, Gabbay RA, Bode B, Garber AJ; INITIATE Study Group. Basal insulin or prernix analogue therapy in type 2 diabetes patients. Eur J Intern Med. 2007;18:56-62.
81. Ratner RE, Hirsch IB, Neifing JL, Garg SK, Mecca TE, Wilson CA. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. US Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care. 2000;23:639-643.
82. Ray JA, Valentine WJ, Roze S, et al. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs insulin glargine in the US. Diabetes Obes Metab. 2007;9:103-113.
83. Reynolds LR, Kingsley FJ, Karounos DG, Tannock LR. Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes. Diabetes Res Clin Pract. 2007;77:180-187.
84. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.
85. Roach P, Malone JK. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with type 2 diabetes. Diabet Med. 2006;23:743-749.
86. Rosenstock J, Park G, Zimmerman J; US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care. 2000;23:1137-1142.
87. Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care. 2001;24:631-636.
88. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care. 2005;28:950-955.
89. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006;29:554-559.
90. Rossetti P, Pampanelli S, Fanelli C, et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care. 2003;26:1490-1496.
91. Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K; Pediatric Study Group of Insulin Glargine. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2002;15:369-376.
92. Scholtz HE, Pretorius SG, Wessels DH, Becker RH. Pharmacokinetic and glucodynamic variability: assessment of insulin glargine. NPH insulin and insulin ultralente in healthy volunteers using a euglycemic clamp technique. Diabetologia. 2005;48:1988-1995.
93. Schreiber SA, Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab. 2007;9:31-38.
94. Secnik Boye K, Matza LS, Oglesby A, et al. Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual Life Outcomes. 2006;4:80.
95. Skyler JS. Effects of glycemic control on diabetes complications and on the prevention of diabetes. Clin Diabetes. 2004;22:162-166.
96. Standi E, Maxeiner S, Raptis S; HOE 901/4009 Study Group. Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride inpatients with type 2 diabetes: an assessment of treatment flexibility. Horm Metab Res. 2006;38:172-177.
97. Triplitt C, Glass L, Miyazaki Y, et al. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea. Diabetes Care. 2006;29:2371-2377.
98. UKPDS (UK Prospective Diabetes Study). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998a;352:837-853.
99. UKPDS (UK Prospective Diabetes Study). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998b;352:854-865.
100. Valentine WJ, Palmer AJ, Erny-Albrecht KM, et al. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH. Adv Ther. 2006;23:191-207.
101. Vinik Al, Zhang Q. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes. Diabetes Care. 2007;30:795-800.
102. Warren E, Weatheriey-Jones E, Chilcoti J, Beverley C. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol Assess. 2004;8:iii, 1-57.
103. WHO (World Health Orgaization). Diabetes mellitus fact sheet no. 312. September 2006. Available at http://www.who.int/inf (accessed January 2007).
104. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes. Diabet Med. 2001;18:619-625.
105. Yki-Järvinen, Dressler A, Ziemen M; HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care. 2000;23:1130-1136.
106. Yki-Järvinen H, Kauppinen-Mäkelin R, Tiikkainen M, et al. Insulin giargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia. 2006;49:442-451.